From University of Oxford trials to NHS pilot programmes, the UK is at the forefront of cannabis research that could reshape modern medicine.
The United Kingdom is quietly becoming a global leader in cannabis research. With over £30 million in funding allocated to cannabinoid studies in 2025-2026, British universities and research institutions are conducting some of the most rigorous and exciting studies in the field.
The University of Oxford’s CARP (Cannabis and Arthritis Research Programme) has enrolled 400 participants in a double-blind, placebo-controlled trial examining cannabis’s effects on inflammatory arthritis. Preliminary results, expected later this year, have already generated significant interest from the medical community.
Meanwhile, the NHS has launched a pilot programme in three London hospitals, integrating cannabis-based treatments into palliative care pathways. Early reports suggest that patients receiving cannabis alongside conventional pain management report significantly higher quality-of-life scores.
Professor James Whitfield, who leads the Oxford study, emphasises the importance of this research: “We need robust clinical evidence to move cannabis from the realm of wellness products into evidence-based medicine. These studies are designed to provide exactly that.”
For companies like Activist, this research validates what we’ve observed anecdotally for years. As the evidence base grows, we’re committed to ensuring our products meet the highest standards of quality and efficacy.